BusinessBeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate SuperiorityBy Nasdaq OMXNov 30, 2017, 2:58 PM UTC
BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
BusinessBeyondSpring Receives Two Grants in China to Further Develop Innovative Drug PipelineBy Nasdaq OMXOct 23, 2017, 12:31 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San FranciscoBy Nasdaq OMXOct 18, 2017, 12:30 PM UTC
BusinessNon-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, OtherBy Nasdaq OMXSep 11, 2017, 11:57 AM UTC
BusinessBiothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung CancerBy Nasdaq OMXJul 19, 2017, 2:00 PM UTC
BusinessPeregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017By Nasdaq OMXJul 7, 2017, 8:05 PM UTC
BusinessBiothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New DrugsBy Nasdaq OMXMar 24, 2017, 2:00 PM UTC
